Using similar science, page-18

I don't like to reply to ploys either. Who would? You wrote earlier "the market seems to side with us and BIIB hasn't made any sort of major move today". You must not have been aware of your error. Today Biogen gained $7.50/share, up 2.47% and closed at $313.59 with high volume.

This "Using similar science" topic has been quite lengthy, not started by either of us, and illustrates an interest in what is going on about AD outside the little world of Prana Biotech. It includes good news for research like Biogen and their licensed partner who were given FDA Fast Track and participation in the EMA's PRIME program. There are others like Lilly/AstraZeneca who also have Fast Track for their BACE Inhibitor and will announce Phase III data later this year. Many who presented at AAIC are moving ahead. There's more to come at medical conferences before the end of the year.